Global Genitourinary Drugs Market Opportunities and Forecast 2020-2027

  • DLR2897
  • 09 January, 2022
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Genitourinary Drugs Market, By Disease Type (Erectile dysfunction ,Gonorrhoea,Genital Herpes,Urinary Tract Infections ,Urinary Incontinence ,Glomerulonephritis,Chronic renal failure,Other Disease Types), By Drug Type(Hormonal Therapy ,Impotence Agents,Uterine Relaxants,Urinary Antispasmodics,Urinary pH Modifiers,Uterine Stimulants,Miscellaneous Genitourinary Tract Agents)and opportunities and forecast 2020-2027

Genitourinary Drugs Market Overview

The increasing disposable incomes of consumers across the world have paved the way for constant advancements within the attention infrastructure. The rising incidences of cancer and genitourinary disorders have additionally boosted the R&D activities related to drug development, adding positive impetus to the demand spurt of sex organ medication.

Genitourinary drugs additionally self-addressed as genitourinary tract agents are medicines employed in the treatment of conditions in the main related to the reproductive organs and therefore the tract.

The increase within the range of patients full of polygenic disorder that square measure extremely susceptible to tract infections (UTI) is another distinguished issue driving the market enlargement. UTIs may be considered the foremost common clinical microorganism infections touching ladies, as they account for nearly twenty fifth of all infections. The urology Care Foundation additionally according that around 60 minutes of ladies and over 12-tone music of men square measure likely to be tormented by the infection at least once throughout their lifetime.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Disease Type,Drug Type, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Pfizer, Inc. Bristol-Myers Squibb Company, Genentech, Inc., F. Hoffmann-La Roche Ltd, Abbott Laboratories, Bayer AG, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Allergan, Merck & Co., Inc.


The covid-19 Impact on Genitourinary Drugs Market:

Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
 
Genitourinary Drugs market Segment Overview



By Disease Type, As there is an increase in the incidence of urinary tract infections, the demand for genitourinary drugs increases, which, in turn, helps in driving the general market. furthermore, the launch of combination drugs, development, and approval of latest drugs, that are additional economical, and therefore the increasing geriatric population are expected to spice up the expansion of the tract infection segment within the global drugs medication market.
 
By Drug Type, Urinary Antispasmodics,the genitourinary drugs market is additionally expected to achieve from increasing incidences of urinary diseases and connected diseases that are sexually transmitted. Moreover, rising concerns regarding urinary incontinence and impotency likewise as technological advancements in genitourinary devices area unit anticipated to accentuate the expansion of the world genitourinary drugs market over the forecast period.
 
Market Analysis, Insights and Forecast – By Disease Type
·       Erectile dysfunction
·       Gonorrhoea
·       Genital Herpes
·       Urinary Tract Infections
·       Urinary Incontinence
·       Glomerulonephritis
·       Chronic renal failure
·       Other Disease Types

Market Analysis, Insights and Forecast – By Drug Type
·       Hormonal Therapy
·       Impotence Agents
·       Uterine Relaxants
·       Urinary Antispasmodics
·       Urinary pH Modifiers
·       Uterine Stimulants
·       Miscellaneous Genitourinary Tract Agents

Genitourinary Drugs Market Regional Overview

Region-wise, in terms of regions ,Asia is expected to expertise a high growth rate within the genitourinary drugs market within the next few years, genitourinary rise in internal organ disease cases, growing need for improved treatments and therapies of genitourinary diseases, increasing awareness concerning internal organ diseases, rise in health care expenditure, and developing health care infrastructure within the region. Growing demographics and economies within the developing countries, like genitourinary and China, are expected to lead to the increase of the genitourinary drugs market within the Asia-Pacific region.

Genitourinary Drugs Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Genitourinary Drugs Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Genitourinary Drugs are highlighted below.

·       In 2020, Bayer received approval from Chinese NMPA (National Medical products Administration) for Xofigo®, utilized in the treatment of castration-resistant prostate cancer (CRPC), and symptomatic bone metastases, in China. The drug is already approved and is employed across 50 global countries, like the U.S., the EU, and Japan.

Genitourinary Drugs Market, Key Players -

·       Pfizer, Inc.
·       Bristol-Myers Squibb Company,
·       Genentech, Inc.,
·       F. Hoffmann-La Roche Ltd,
·       Abbott Laboratories,
·       Bayer AG,
·       Novartis AG,
·       Eli Lilly and Company,
·       Teva Pharmaceutical Industries Ltd.,
·       Allergan, Merck & Co., Inc.
 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Genitourinary Drugs Market during the forecast period?

A. Genitourinary Drugs market is expected to record a CAGR of ~ 2.1% during the forecast period.

Q2. Which segment is projected to hold the largest share in the Genitourinary Drugs Market?

A. Urinary Tract Infections segment is projected to hold the largest share in the Genitourinary Drugs Market

Q3. What are the driving factors for the Genitourinary Drugs Market?

A. The increase in urinary and sexual diseases, the growing variety of pipeline studies , these are main factors driving the growth of automotive lighting market

Q4. Which Segments are covered in the Genitourinary Drugs Market report?

A. Disease Type, Drug Type and Region, these segments are covered in the Genitourinary Drugs Market report

Q5. Which are the prominent players offering Genitourinary Drugs Market?

A. Pfizer, Inc. Bristol-Myers Squibb Company, Genentech, Inc., F. Hoffmann-La Roche Ltd, Abbott Laboratories, Bayer AG, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Allergan, Merck & Co., Inc
Genitourinary Drugs Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Genitourinary Drugs Market analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Disease Type
        • 5.2.1. •Erectile dysfunction
        • 5.2.2. •Gonorrhoea
        • 5.2.3. •Genital Herpes
        • 5.2.4. •Urinary Tract Infections
        • 5.2.5. •Urinary Incontinence
        • 5.2.6. •Glomerulonephritis
        • 5.2.7. •Chronic renal failure
        • 5.2.8. •Other Disease Types
      • 5.3. Market Analysis, Insights and Forecast – By Drug Type
        • 5.3.1. •Hormonal Therapy
        • 5.3.2. •Impotence Agents
        • 5.3.3. •Uterine Relaxants
        • 5.3.4. •Urinary Antispasmodics
        • 5.3.5. •Urinary pH Modifiers
        • 5.3.6. •Uterine Stimulants
        • 5.3.7. •Miscellaneous Genitourinary Tract Agents
      • 5.4. Market Analysis, Insights and Forecast – By Region
        • 5.4.1. North America
        • 5.4.2. Europe
        • 5.4.3. Asia Pacific
        • 5.4.4. Latin America, Middle East, and Africa

      6. North America Genitourinary Drugs Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Disease Type
        • 6.2.1. •Erectile dysfunction
        • 6.2.2. •Gonorrhoea
        • 6.2.3. •Genital Herpes
        • 6.2.4. •Urinary Tract Infections
        • 6.2.5. •Urinary Incontinence
        • 6.2.6. •Glomerulonephritis
        • 6.2.7. •Chronic renal failure
        • 6.2.8. •Other Disease Types
      • 6.3. Market Analysis, Insights and Forecast – By Drug Type
        • 6.3.1. •Hormonal Therapy
        • 6.3.2. •Impotence Agents
        • 6.3.3. •Uterine Relaxants
        • 6.3.4. •Urinary Antispasmodics
        • 6.3.5. •Urinary pH Modifiers
        • 6.3.6. •Uterine Stimulants
        • 6.3.7. •Miscellaneous Genitourinary Tract Agents
      • 6.4. Market Analysis, Insights and Forecast – By Country
        • 6.4.1. UK
        • 6.4.2. Germany
        • 6.4.3. France
        • 6.4.4. Italy
        • 6.4.5. Spain
        • 6.4.6. Russia
        • 6.4.7. Rest of Europe

      7. Asia Pacific Genitourinary Drugs Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Disease Type
        • 7.2.1. •Erectile dysfunction
        • 7.2.2. •Gonorrhoea
        • 7.2.3. •Genital Herpes
        • 7.2.4. •Urinary Tract Infections
        • 7.2.5. •Urinary Incontinence
        • 7.2.6. •Glomerulonephritis
        • 7.2.7. •Chronic renal failure
        • 7.2.8. •Other Disease Types
      • 7.3. Market Analysis, Insights and Forecast – By Drug Type
        • 7.3.1. •Hormonal Therapy
        • 7.3.2. •Impotence Agents
        • 7.3.3. •Uterine Relaxants
        • 7.3.4. •Urinary Antispasmodics
        • 7.3.5. •Urinary pH Modifiers
        • 7.3.6. •Uterine Stimulants
        • 7.3.7. •Miscellaneous Genitourinary Tract Agents
      • 7.4. Market Analysis, Insights and Forecast – By Country
        • 7.4.1. China
        • 7.4.2. India
        • 7.4.3. Japan
        • 7.4.4. Australia
        • 7.4.5. South East Asia
        • 7.4.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Genitourinary Drugs Market Analysis(USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Disease Type
        • 8.2.1. •Erectile dysfunction
        • 8.2.2. •Gonorrhoea
        • 8.2.3. •Genital Herpes
        • 8.2.4. •Urinary Tract Infections
        • 8.2.5. •Urinary Incontinence
        • 8.2.6. •Glomerulonephritis
        • 8.2.7. •Chronic renal failure
        • 8.2.8. •Other Disease Types
      • 8.3. Market Analysis, Insights and Forecast – By Drug Type
        • 8.3.1. •Hormonal Therapy
        • 8.3.2. •Impotence Agents
        • 8.3.3. •Uterine Relaxants
        • 8.3.4. •Urinary Antispasmodics
        • 8.3.5. •Urinary pH Modifiers
        • 8.3.6. •Uterine Stimulants
        • 8.3.7. •Miscellaneous Genitourinary Tract Agents
      • 8.4. Market Analysis, Insights and Forecast – By Country
        • 8.4.1. Brazil
        • 8.4.2. Saudi Arabia
        • 8.4.3. UAE
        • 8.4.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Pfizer Inc.,
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. • Bristol-Myers Squibb Company,
      • 9.6. •Genentech, Inc.,
      • 9.7. • F. Hoffmann-La Roche Ltd,
      • 9.8. •Abbott Laboratories,
      • 9.9. • Bayer AG,
      • 9.10. • Novartis AG,
      • 9.11. • Eli Lilly and Company,
      • 9.12. •Teva Pharmaceutical Industries Ltd.,

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934